Cell therapy for ARDS: efficacy of endobronchial versus intravenous administration and biodistribution of MAPCs in a large animal model

Abstract

IntroductionBone marrow-derived multipotent adult progenitor cells (MAPCs) are adult allogeneic adherent stem cells currently investigated clinically for use in acute respiratory distress syndrome (ARDS). To date, there is no agreement on which is the best method for stem cells delivery in ARDS. Here, we compared the efficacy of two different methods of administration and biodistribution of MAPC for the treatment of ARDS in a sheep model.MethodsMAPC were labelled with [18F] fluoro-29-deoxy-D-glucose and delivered by endobronchial (EB) or intravenous route 1 hour after lipopolysaccharide infusion in sheep mechanically ventilated. PET/CT images were acquired to determine the biodistribution and retention of the cells at 1 and 5 hours of administration.ResultsThe distribution and retention of the MAPC was dependent on the method of cell administration. By EB route, PET images showed that MAPC remained at the site of administration and no changes were observed after 5 hours, whereas with intravenous route, the cells had broad biodistribution to different organs, being the lung the main organ of retention at 1 and 5 hours. MAPC demonstrated an equal effect on arterial oxygenation recovery by either route of administration.ConclusionThe EB or intravenous routes of administration of MAPC are both effective for the treatment of ARDS in an acute sheep model, and the effect of MAPC therapy is not dependent of parenchymal integration or systemic biodistribution.

Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises

“…Also, MSCs can reduce the concentrations of pro-inflammatory cytokines like IL1α, TNFα, IL6, IL12, and IFNγ, and therefore limiting the formation of cytokine storm [40,41]. Studies show the effects of MSCs in the treatment of acute lung injury and chronic lung disease [42]. A previous study found that MSCs can help to attenuate acute lung injury and ischemia-reperfusion mediated lung injury caused by lipopolysaccharide [43].…”

Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure

“…MSC therapeutic effectiveness is likely limited to a niche of immunological disorders and immune-mediated illnesses such as graft-versus-host-disease, for which MSCs have demonstrated varying levels of efficacy in Phase 1/2 clinical studies 31 , 32 . In multiple pre-clinical studies, MSCs have been shown to be effective against ARDS and acute lung injury (ALI) 33 , 34 , both of which are severe clinical manifestations of COVID-19, and while, administration of MSCs to subjects with ARDS was well tolerated 35 , 36 , efficacy data at the clinical level is not as compelling. To date, there are about 40 clinical trials registered on clinicaltrials.gov for evaluating the use of MSCs in subjects with COVID-19 (Table 1 ) 37 .…”

Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients

“…The treatment has been followed by a reduction in inflammatory parameters (CRP, ferritin, LDH, IL-6) as well as increase in B-lymphocytes (67%) and CD4 + and CD8 + (100%) T lymphocytes). Remarkably, a reduction of D-dimer and fibrinogen 5 days after the first dose of AT-MSCs has been observed in most patients, and the patients do not develop a thromboembolic event [ 169 , 170 ].…”